BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16409301)

  • 1. P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors.
    Brusa G; Zuffa E; Mancini M; Benvenuti M; Calonghi N; Barbieri E; Santucci MA
    Br J Haematol; 2006 Feb; 132(3):359-69. PubMed ID: 16409301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
    Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
    Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPO-trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloid leukaemia.
    Mancini M; Zuffa E; Veljkovic N; Brusa G; Corrado P; Corradi V; Martinelli G; Barbieri E; Santucci MA
    Br J Haematol; 2008 Jun; 141(6):899-902. PubMed ID: 18373703
    [No Abstract]   [Full Text] [Related]  

  • 4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
    Xu Y; Voelter-Mahlknecht S; Mahlknecht U
    Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
    Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
    Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
    Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
    Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
    Møller GM; Frost V; Melo JV; Chantry A
    FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
    Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
    Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
    Toh Y; Yamamoto M; Endo K; Ikeda Y; Baba H; Kohnoe S; Yonemasu H; Hachitanda Y; Okamura T; Sugimachi K
    Oncol Rep; 2003; 10(2):333-8. PubMed ID: 12579268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats.
    Bai XT; Gu BW; Yin T; Niu C; Xi XD; Zhang J; Chen Z; Chen SJ
    Cancer Res; 2006 May; 66(9):4584-90. PubMed ID: 16651408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.
    Underhill-Day N; Pierce A; Thompson SE; Xenaki D; Whetton AD; Owen-Lynch PJ
    Br J Haematol; 2006 Mar; 132(6):774-83. PubMed ID: 16487179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.